Research progress on Marburg virus disease

doi:10.19871/j.cnki.xfcrbzz.2025.01.015

Abstract

Abstract: Since its first discovery during outbreaks in Marburg, Germany, Frankfurt, and Yugoslavia in 1967, the Marburg virus disease has caused multiple high-fatality epidemics on various continents, primarily concentrated in sub-Saharan Africa. Belonging to the Filoviridae family, the virus often leads to severe hemorrhagic fever in infected individuals, followed by organ failure and death. The Marburg virus disease can be transmitted person-to-person in household or healthcare settings. Currently, there are no effective preventive or therapeutic measures available. However, systematic supportive care can improve survival rates. In order to proactively address potential future outbreaks, this article provides a comprehensive review of the virology, pathological features, clinical manifestations, diagnostics, antiviral drugs, vaccine development, and preventative strategy of the Marburg virus disease. The aim is to enhance the understanding of healthcare professionals in China regarding this virus and provide direct or indirect theoretical and practical references for future prevention and control efforts against potential outbreaks.

Key words: Marburg virus disease, Pathological features, Clinical manifestations, Antiviral drugs, Vaccine development

CLC Number:

R511

Yao Weiming, Wang Fuxiang, Zhang Peiyan, Lu Hongzhou. Research progress on Marburg virus disease[J]. Electronic Journal of Emerging Infectious Diseases, 2025, 10(1): 77-81.

References

[1] KORTEPETER MG, DIERBERG K, SHENOY ES, et al.Marburg virus disease: A summary for clinicians[J].Int J Infect Dis, 2020, 99: 233-242.
[2] BRAUBURGER K, HUME AJ, MUHLBERGER E, et al.Forty-five years of Marburg virus research[J].Viruses, 2012, 4(10): 1878-1927.
[3] WHO. Ebola and Marburg virus disease epidemics: preparedness, alert, control, and evaluation[EB/OL].[2024-08-06].https://www.who.int/publications/i/item/ebola-and-marburg-virus-disease-epidemics-preparedness-alert-control-and-evaluation.
[4] UWISHEMA O.First Marburg virus outbreak in Rwanda: urgent actions needed[J].Lancet, 2024, 404(10463): 1639.
[5] CUOMO-DANNENBURG G, MCCAIN K, MCCABE R, et al.Marburg virus disease outbreaks, mathematical models, and disease parameters: a systematic review[J].Lancet Infect Dis, 2024, 24(5): e307-e317.
[6] JANUS BM, WANG R, CLEVELAND TE 4TH, et al. Macaque antibodies targeting Marburg virus glycoprotein induced by multivalent immunization[J].J Virol, 2024, 98(7): e0015524.
[7] GUITO JC, KIREJCZYK SGM, SCHUH AJ, et al.Coordinated inflammatory responses dictate Marburg virus control by reservoir bats[J].Nat Commun, 2024, 15(1): 1826.
[8] SHIFFLETT K, MARZI A.Marburg virus pathogenesis - differences and similarities in humans and animal models[J].Virol J, 2019, 16(1): 165.
[9] HOFFMANN M, CRONE L, DIETZEL E, et al.A polymorphism within the internal fusion loop of the Ebola virus glycoprotein modulates host cell entry[J].J Virol, 2017, 91(9): 1-14.
[10] CROSS RW, MIRE CE, FELDMANN H, et al.Post-exposure treatments for Ebola and Marburg virus infections[J].Nat Rev Drug Discov, 2018, 17(6): 413-434.
[11] BORCHERT M, MULANGU S, SWANEPOEL R, et al.Serosurvey on household contacts of Marburg hemorrhagic fever patients[J].Emerg Infect Dis, 2006, 12(3): 433-439.
[12] BAUER MP, TIMEN A, VOSSEN ACTM, et al.Marburg haemorrhagic fever in returning travellers: an overview aimed at clinicians[J].Clin Microbiol Infect, 2019, 21S: e28-e31.
[13] WHO. Marburg virus disease[EB/OL].[2024-10-23].https://www.who.int/news-room/fact-sheets/detail/marburg-virus-disease.
[14] BIXLER SL, BOCAN TM, WELLS J, et al.Efficacy of favipiravir (T-705) in nonhuman primates infected with Ebola virus or Marburg virus[J].Antiviral Res, 2018, 151: 97-104.
[15] PORTER DP, WEIDNER JM, GOMBA L, et al.Remdesivir (GS-5734) Is Efficacious in Cynomolgus Macaques Infected With Marburg Virus[J].J Infect Dis, 2020, 222(11): 1894-1901.
[16] DIAZ AM, SMITH LM, PETERSON AN, et al.Impact of Pharmacist Inhaler Prescribing at Discharge for Chronic Obstructive Pulmonary Disease on Readmission Rates[J].Chronic Obstr Pulm Dis, 2025, 12(1): 43-51.
[17] DYE JM, HERBERT AS, KUEHNE AI, et al.Postexposure antibody prophylaxis protects nonhuman primates from filovirus disease[J].Proc Natl Acad Sci USA, 2012, 109(13): 5034-5039.
[18] MIRE CE, GEISBERT JB, BORISEVICH V, et al. Therapeutic treatment of Marburg and Ravn virus infection in nonhuman primates with a human monoclonal antibody[J].Sci Transl Med, 2017, 9(384): eaai8711.
[19] URSIC-BEDOYA R, MIRE CE, ROBBINS M, et al.Protection against lethal Marburg virus infection mediated by lipid encapsulated small interfering RNA[J].J Infect Dis, 2014, 209(4): 562-570.
[20] THI EP, MIRE CE, URSIC-BEDOYA R, et al. Marburg virus infection in nonhuman primates: Therapeutic treatment by lipid-encapsulated siRNA[J].Sci Transl Med, 2014, 6(250): 250ra116.
[21] WOOLSEY C, GEISBERT JB, MATASSOV D, et al.Postexposure Efficacy of Recombinant Vesicular Stomatitis Virus Vectors Against High and Low Doses of Marburg Virus Variant Angola in Nonhuman Primates[J].J Infect Dis, 2018, 218(suppl_5): S582-S587.
[22] CALLAWAY E.Deadly Marburg virus: scientists race to test vaccines in outbreak[J].Nature, 2024, 634(8033): 278.
[23] REYNOLDS P, MARZI A.Ebola and Marburg virus vaccines[J].Virus Genes, 2017, 53(4): 501-515.
[24] SUSCHAK JJ, SCHMALJOHN CS.Vaccines against Ebola virus and Marburg virus: recent advances and promising candidates[J].Hum Vaccin Immunother, 2019, 15(10): 2359-2377.
[25] ALLA D, PARUCHURI SSH, TIWARI A, et al.The mortality, modes of infection, diagnostic tests, and treatments of Marburg virus disease: A systematic review[J].Health Sci Rep, 2023, 6(9): e1545.
[26] KARAMI H, LETAFATI A, FAKHR SSH.Can Marburg virus be sexually transmitted?[J].Health Sci Rep, 2024, 7(8): e2270.
[27] KUMING BS, KOKORIS N.Uveal involvement in Marburg virus disease[J].Br J Ophthalmol, 1977, 61(4): 265-266.